Topol warns that letting unapproved peptides be sold via compounding lists reduces incentives for clinical trials and leaves consumers vulnerable to aggressive sellers.

The chances of clinical trials getting done now are diminished. We will have more people who are prey to predators that will sell, sell, sell.

Topol argues that peptide promoters claiming success should reinvest profits into rigorous clinical research.

If influencers and companies really believe these peptides are helping people, then they should put their profits back into rigorous research.

Topol argues medicine must shift from reactive treatment of sickness to prevention, and believes it will.

the fact that we are only treating, treating, treating, trying to deal with sick, sick sickness instead of preventing, preventing, preventing that's the shift that has to take place. And I believe it will in the future.

Topol says smartwatch atrial fibrillation detection is now about 99% sensitive and specific, a major medical advance.

the ability to diagnose atrial fibrillation now through your wristband watch it's so accurate now. It's like 99% sensitive 99% specific. it's really been extraordinary picking up what is a very serious arrhythmia for its stroke risk

Topol warns that shrinking clinic visit times to 12 minutes has eroded the patient-doctor relationship.

the time with a patient for a clinic appointment was being dropped steadily from a new patient, like, have an hour to having 12 minutes. Right. And, you know, to be able to get the entire history of a person and to respond to their concerns and what needs to be done in 12 minutes of somebody you've never seen before. It's ridiculous.